Literature DB >> 19229589

High diagnostic value of morphologic examination and molecular analysis of bone marrow biopsies in a case of BCR-ABL+ CML with clusters of blasts.

Eva Markert1, Udo Siebolts2,3, Margarete Odenthal1, Karl-Anton Kreuzer4, Claudia Wickenhauser5,6.   

Abstract

We report a clinical case of chronic myelogenous leukaemia (CML) with regional B-lymphoblastic transformation. Peripheral leukocytosis of 160 x 10(9)/L, splenomegaly and fatigue suggested CML. In peripheral blood and bone marrow smears, white blood cells in all maturation stages and only few blasts were seen and therefore the diagnosis of chronic phase CML was proposed. Cytogenetics performed on peripheral blood cells revealed the characteristic t(9;22)(q34;q11) translocation as solitary abnormality. Analyzing the bone marrow biopsy a focal nodular B-lymphoid blast component was additionally seen. BCR-ABL FISH analysis demonstrated 31% atypical split signals in the B-lymphoid blasts and in the maturing myeloid cells, furthermore, BCR-ABL fusion transcripts were seen in the RT-PCR assay. Imatinib-based therapy led to temporary regression of peripheral leukocytosis. Bone marrow examination 3 weeks after therapy induction demonstrated considerably reduced cellularity and the proportion of B-lymphoid blasts had decreased to 20% of the nuclear cells. BCR-ABL FISH analysis still presented 21% atypical split signals but levels of BCR-ABL transcripts had significantly fallen indicating a rather favourable prognosis. However, 3 months after diagnosis the patient relapsed and developed an immunodeficiency with soor esophagitis and aspergillus pneumonia. A therapy with dasatinib was not successful and the patient died in consequence of immunodeficiency. This report demonstrates the high diagnostic value of bone marrow biopsy in the evaluation of CML. Besides morphology investigation of diverse methods including RT-PCR and FISH performed on diagnostic bone marrow biopsies are obligatory for ideal monitoring of drug response.

Entities:  

Mesh:

Year:  2009        PMID: 19229589     DOI: 10.1007/s12185-009-0257-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  8 in total

1.  Pathobiology of lymphoid and myeloid blast crisis and management issues.

Authors:  Robert L Ilaria
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

2.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

Authors:  Charles L Sawyers; Andreas Hochhaus; Eric Feldman; John M Goldman; Carole B Miller; Oliver G Ottmann; Charles A Schiffer; Moshe Talpaz; Francois Guilhot; Michael W N Deininger; Thomas Fischer; Steve G O'Brien; Richard M Stone; Carlo B Gambacorti-Passerini; Nigel H Russell; Jose J Reiffers; Thomas C Shea; Bernard Chapuis; Steven Coutre; Sante Tura; Enrica Morra; Richard A Larson; Alan Saven; Christian Peschel; Alois Gratwohl; Franco Mandelli; Monique Ben-Am; Insa Gathmann; Renaud Capdeville; Ronald L Paquette; Brian J Druker
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

3.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.

Authors:  Christian W Scharenberg; Michael A Harkey; Beverly Torok-Storb
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

4.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

5.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

Authors:  Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; Francois Guilhot; Charles A Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

6.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Authors:  Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; Francois Guilhot; Charles Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole Miller; Martin Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

7.  Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.

Authors:  Hagop Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Deborah Thomas; Steven Kornblau; Jianquin Shan; Mary Beth Rios; Michael Keating; Emil Freireich; Moshe Talpaz
Journal:  Cancer       Date:  2003-07-01       Impact factor: 6.860

8.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Authors:  Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

  8 in total
  1 in total

1.  Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.

Authors:  Kaoru Tamura; Hiroaki Wakimoto; Aayush S Agarwal; Samuel D Rabkin; Deepak Bhere; Robert L Martuza; Toshihiko Kuroda; Randa Kasmieh; Khalid Shah
Journal:  Mol Ther       Date:  2012-08-28       Impact factor: 11.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.